Insiders Trades
ST
Soleno Therapeutics Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 28 Sept 2023.
Soleno Therapeutics Inc: what insiders have been doing
Soleno Therapeutics Inc, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Over the twelve months to 18 October 2026, the company's managers filed 23 filings, from 9 insiders.
No insider bought on the market over the period, while 2 insiders filed 6 sales totalling €372k. Biggest ticket of the year: €127k, sold by Manning Meredith and made public on 31 March 2026.
With 23 filings in twelve months, the company is more active than the median of 22 filings across the 5,458 companies we follow on the same exchange. The full history, which starts in 2016, counts 13 purchases against 61 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 190.4 m USD and net income at 20.9 m USD.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
154
Thresholds
n/a
Buy Volume
€737,266
13 ops. · all time
Sell Volume
€92M
61 ops. · all time
Who traded when
BuySaleMeredith Manning4 sales
Michael F. Huang4 sales
Patricia C. Hirano4 sales
Bhatnagar Anish2 sales
James H. Mackaness2 sales
Kristen Yen2 sales
+1 other insider
Since the insiders bought
- +130.9%Entry US$23.85 · Close at T+365 US$55.06
- +12.4%Entry US$3.00 · Close at T+365 US$3.37
- +12.4%Entry US$3.00 · Close at T+365 US$3.37
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Soleno Therapeutics Inc Hold (neutral), based on 5 analysts. Average price target: US$53.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 7,951 of 24,148 companies
60.1
score / 100
Value42
Quality78
FCF yld1.7%
Earn yld0.7%
EV/EBITDA·
ROE26%
Gross mgn99%
Net mgn11%
Debt/EBITDA1.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$53.01
Analyst consensus
5 analystsHold
US$53.00Target US$53.00(-0%)US$53.00
Income statement
RevenueUS$190.4M
Gross profitUS$187.7M99% margin
EBITDAUS$28.4M15% margin
Net incomeUS$20.5M33.7% margin
Valuation
PER (trailing)27.5x
P/Book6.2x
Beta-2.22
Balance sheet & cash
Market capUS$2.8B
Total debtUS$52.6M
Free Cash FlowUS$46.7M
Debt / Equity11%
Profitability & ownership
ROE26.4%
ROA12.1%
% insiders1.3%
% institutions111.5%
Last declaration on 31 March 2026
Declarations154 total
4,256 shares@ US$30.03748.0% of flowCommon StockSEC:0002019992-26-000002:0
1,838 shares@ US$31.038421.4% of flowCommon StockSEC:0002019992-26-000002:1
488 shares@ US$31.71875.8% of flowCommon StockSEC:0002019992-26-000002:2
4,864 shares@ US$30.03739.4% of flowCommon StockSEC:0001752631-26-000002:0
2,100 shares@ US$31.038417.6% of flowCommon StockSEC:0001752631-26-000002:1
558 shares@ US$31.71874.8% of flowCommon StockSEC:0001752631-26-000002:2
39,200 shares0Common StockSEC:0001873522-26-000007:0
10,400 shares0Common StockSEC:0001643441-26-000001:0
10,400 shares0Common StockSEC:0002019992-26-000001:0
4,100 shares0Common StockSEC:0001978048-26-000001:0
3,500 shares0Common StockSEC:0001819690-26-000002:0
10,400 shares0Common StockSEC:0001766042-26-000001:0
28,600 shares0Common StockSEC:0001752631-26-000001:0
114,200 shares0Common StockSEC:0001614821-26-000001:0
28,600 shares0Common StockSEC:0001422484-26-000001:0
812 shares@ US$49.9515.0% of flowCommon StockSEC:0002019992-25-000003:0
904 shares@ US$49.952.5% of flowCommon StockSEC:0001766042-25-000003:0
1,922 shares@ US$49.9525.5% of flowCommon StockSEC:0001752631-25-000004:0
904 shares@ US$49.953.9% of flowCommon StockSEC:0001643441-25-000003:0
7,620 shares@ US$49.953.7% of flowCommon StockSEC:0001614821-25-000005:0
2,013 shares@ US$49.956.1% of flowCommon StockSEC:0001422484-25-000003:0
14,286 shares0Common StockSEC:0001819690-25-000008:0
16,071 shares0Common StockSEC:0001978048-25-000003:0
10,046 shares0Common StockSEC:0001408502-25-000008:0
3,830 shares@ US$82.7617.6% of flowCommon StockSEC:0001415889-25-019336:0
25 of 154 declarations
About Soleno Therapeutics Inc
Soleno Therapeutics Inc. (NASDAQ: SLNO) is a United States-based biopharmaceutical company headquartered in Redwood City, California. For French-speaking investors, Soleno is best understood as a rare-disease specialist whose equity story is built around moving from clinical/regulatory execution into commercialization. The company previously operated under the name Capnia, Inc. and changed its name to Soleno Therapeutics in 2017, underscoring a strategic pivot toward a more focused rare-disease platform. ([stockanalysis.com](https://stockanalysis.com/stocks/slno/company/?utm_source=openai))
Soleno’s core business is the development and commercialization of novel therapies for rare diseases, with a particular emphasis on conditions marked by serious unmet medical need. Its lead asset, VYKAT XR, sits at the center of the investment case and has been the key driver of the company’s transition from a development-stage biotech into a company with commercial ambitions. In its 2024 annual report, Soleno describes itself as a biopharmaceutical company focused on rare diseases and notes that it has divested legacy business efforts in order to concentrate on this core mission. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1484565/000095017025029545/slno-20241231.htm?utm_source=openai))
Read moreShow less
From a competitive standpoint, Soleno operates in a highly specialized niche where the addressable patient population is small, but clinical differentiation can be economically meaningful. In rare diseases, success depends on more than regulatory approval: commercialization quality, reimbursement access, physician awareness, and post-launch execution all matter materially. That makes Soleno’s market position one of a focused specialist rather than a broad diversified pharma player. The opportunity is attractive precisely because barriers to entry are high and the value of a successful product can be significant relative to the size of the company. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1484565/000095017025029545/slno-20241231.htm?utm_source=openai))
Geographically, Soleno is a U.S. company with operations and corporate headquarters in California, and it is listed on the NASDAQ, giving it visibility among U.S. biotech investors and event-driven market participants. For investors in France, Belgium, and Switzerland, this means SLNO should be viewed as a U.S.-listed healthcare name with the reporting depth of a SEC registrant and the typical volatility profile of a small-cap biotech transitioning toward commercialization. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1484565/000095017025029545/0000950170-25-029545-index.html?utm_source=openai))
Recent developments have been dominated by the company’s regulatory and commercial progress around VYKAT XR. Soleno’s 2024 SEC filing highlighted the FDA’s acceptance of the NDA, priority review designation, and a PDUFA target date of December 27, 2024, marking an important milestone in its path to market. More broadly, recent market coverage suggests that investors increasingly frame Soleno as a commercialization story tied to a lead rare-disease asset, rather than as a purely clinical-stage developer. For equity analysts, the key monitoring points remain product uptake, payer access, regulatory follow-through, and the durability of the launch trajectory. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1484565/000095017025029545/slno-20241231.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
